<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02565173</url>
  </required_header>
  <id_info>
    <org_study_id>IPC-01-2015</org_study_id>
    <nct_id>NCT02565173</nct_id>
  </id_info>
  <brief_title>Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma</brief_title>
  <acronym>MATrX-1</acronym>
  <official_title>Phase III Multi-center, Randomized, Double-masked, Active- and Placebo-controlled Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inotek Pharmaceuticals Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inotek Pharmaceuticals Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase III trial involving topical application, in both eyes, of trabodenoson ophthalmic
      formulation 3.0% or 6.0% once per day or 4.5% twice per day, placebo twice per day, or
      timolol 0.5% twice per day for 12 weeks in adult subjects with Ocular Hypertension or Primary
      Open-Angle Glaucoma.

      All subjects who meet the study's enrollment criteria following Screening will undergo
      washout of all prohibited medications, including their routine glaucoma medications. During
      the Placebo Run-In Period, placebo is administered twice daily to both eyes in all subjects.
      During the Treatment Period, study drug is applied to both eyes for a total of 12 weeks
      followed by an Observation Period of approximately 7 days wherein no study eye drops are
      instilled.

      The purpose of the study is to assess the efficacy, tolerability, and safety of binocular
      topical application of trabodenoson ophthalmic formulation 3.0% or 6.0% QD or 4.5% BID for 12
      weeks.

      Timolol is being included in the trial in order to have an active control to ensure the
      integrity of the trial from an efficacy perspective; the primary comparator for all
      statistical purposes is the placebo arm.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Intraocular Pressure (IOP)</measure>
    <time_frame>Three Months</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Safety Parameters, including treatment emergent adverse events, to assess tolerability and safety.</measure>
    <time_frame>Through Study Completion, up to 13 weeks.</time_frame>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">303</enrollment>
  <condition>Primary Open-Angle Glaucoma (POAG)</condition>
  <condition>Ocular Hypertension (OHT)</condition>
  <arm_group>
    <arm_group_label>trabodenoson 4.5% BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>trabodenoson 4.5% Ophthalmic Formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>trabodenoson 6.0% QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>trabodenoson 6.0% Ophthalmic Formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>trabodenoson 3.0% QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>trabodenoson 3.0% Ophthalmic Formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>timolol 0.5% BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>timolol 0.5% Ophthalmic Formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo BID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo Ophthalmic Formulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trabodenoson 4.5% BID</intervention_name>
    <description>Trabodenoson 4.5% administered twice per day in both eyes for 12 weeks.</description>
    <arm_group_label>trabodenoson 4.5% BID</arm_group_label>
    <other_name>INO-8875</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trabodenoson 6.0% QD</intervention_name>
    <description>Trabodenoson 6.0% administered once per day in the morning in both eyes followed by matching placebo administered once per day in the evening in both eyes for 12 weeks.</description>
    <arm_group_label>trabodenoson 6.0% QD</arm_group_label>
    <other_name>INO-8875</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trabodenoson 3.0% QD</intervention_name>
    <description>Trabodenoson 3.0% administered once per day in the morning in both eyes followed by matching placebo administered once per day in the evening in both eyes for 12 weeks.</description>
    <arm_group_label>trabodenoson 3.0% QD</arm_group_label>
    <other_name>INO-8875</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>timolol 0.5% BID</intervention_name>
    <description>Timolol 0.5% administered twice per day in both eyes for 12 weeks.</description>
    <arm_group_label>timolol 0.5% BID</arm_group_label>
    <other_name>Timoptic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo BID</intervention_name>
    <description>Placebo administered twice per day in both eyes for 12 weeks.</description>
    <arm_group_label>placebo BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of ocular hypertension (OHT) or primary open-angle glaucoma (POAG)

          -  Mean Intraocular pressure (IOP) of ≥24 and ≤34

        Exclusion Criteria:

          -  Significant visual field loss or any new field loss within the past year

          -  Cup-to-disc ratio &gt;0.8

          -  Central corneal thickness &lt;490 µm or &gt;610 µm

          -  A recent (acute) or chronic medical condition that might obfuscate the Subject's study
             data
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cadmus C Rich, MD,MBA,CPE</last_name>
    <role>Study Director</role>
    <affiliation>Inotek Pharmaceuticals Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inotek Pharmaceuticals Corporation</name>
      <address>
        <city>Lexington</city>
        <state>Massachusetts</state>
        <zip>02421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2015</study_first_submitted>
  <study_first_submitted_qc>September 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2015</study_first_posted>
  <last_update_submitted>December 2, 2016</last_update_submitted>
  <last_update_submitted_qc>December 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glaucoma</keyword>
  <keyword>primary open-angle glaucoma</keyword>
  <keyword>ocular hypertension</keyword>
  <keyword>adenosine agonist</keyword>
  <keyword>eye drop</keyword>
  <keyword>trabodenoson</keyword>
  <keyword>trabecular meshwork</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Timolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

